Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo

Oncology Reports

Volumn 29, Issue 2, 2013, Pages 515-522

  Mao, Hong Luan ^a   Pang, Yingxin ^a   Zhang, Xiaolei ^a   Yang, Fang ^a   Zheng, Jingfang ^a   Wang, Yu ^a   Liu, Peishu ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Epithelial ovarian cancer; Paclitaxel; Peptide; Second mitochondria derived activator of caspase; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE N7 PEPTIDE; SURVIVIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NECROSIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGOPEPTIDES; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; SKIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84872790310     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2132     Document Type: Article

References (29)

1. Lee J Y, Shin J Y, Kim HS, et al: Effect of combined treatment with progesterone and tamoxifen on the growth and apoptosis of human ovarian cancer cells. Oncol Rep 27: 87-93, 2012.
2. Fesik SW: Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev 5: 876-885, 2005. (Pubitemid 41746032)
3. Sayers TJ: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 60: 1173-1180, 2011.
4. Qiu W, Liu H, Sebastini A, Sun Q, Wang H, Zhang L and Yu J: An apoptosis-independent role of SMAC in tumor suppression. Oncogene: Jul 2, 2012 (Epub ahead of print).
5. Fulda S and Vucic D: Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11: 109-124, 2012.
6. De Almagro MC and Vucic D: The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol 34: 200-211, 2012.
7. Chai J, Du C, Wu JW, Kyin S, Wang X and Shi Y: Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406: 855-862, 2000. (Pubitemid 30664254)
8. Du C, Fang M, Li Y, Li L and Wang X: Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33-42, 2000.
9. Liu Z, Sun C, Olejniczak ET, et al: Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature 408: 1004-1008, 2000. (Pubitemid 32101650)
10. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ and Kaufmann SH: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem 277: 44236-44243, 2002. (Pubitemid 36157856)
11. Giagkousiklidis S, Vogler M, Westhoff MA, Kasperczyk H, Debatin KM and Fulda S: Sensitization for gamma-irradiation-induced apoptosis by second mitochondria-derived activator of caspase. Cancer Res 65: 10502-10513, 2005. (Pubitemid 41743746)
12. Rein DT, Volkmer AK, Volkmer J, et al: Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer. Oncol Lett 3: 530-534, 2012.
13. Krasner CN, Poveda A, Herzog TJ, et al: Patient-reported outcomes in relapsed ovarian cancer: Results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD Alone. Gynecol Oncol 127: 161-167 2012.
14. Mulier S, Claes J P, Dierieck V, et al: Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des 18: 3793-3803 2012.
15. Mao HL, Liu PS, Zheng JF, Zhang PH, Zhou LG, Xin G and Liu C: Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro. Pharmacol Res 56: 483-492, 2007. (Pubitemid 350137770)
16. Oost TK, Sun C, Armstrong RC, et al: Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem 47: 4417-4426, 2004. (Pubitemid 39096830)
17. Bianchi A, Ugazzi M, Ferrante L, Lecis D, Scavullo C, Mastrangelo E and Seneci P: Rational design, synthesis and characterization of potent, drug-like monomeric Smac mimetics as pro-apoptotic anticancer agents. Bioorg Med Chem Lett 22: 2204-2208, 2012.
18. Yang D, Zhao Y, Li AY, Wang S, Wang G and Sun Y: Smacmimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. Breast Cancer Res Treat 133: 189-199, 2012.
19. Voelkel-Johnson C: TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 8: 417-427, 2011.
20. Kauntz H, Bousserouel S, Gossé F and Raul F: The flavonolignan silibinin potentiates TRAIL-induced apoptosis in human colon adenocarcinoma and in derived TRAIL-resistant metastatic cells. Apoptosis 17: 797-809, 2012.
21. Fandy TE, Shankar S and Srivastava RK: Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 7: 60, 2008.
22. Boere IA and van der Burg ME: Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer. Curr Pharm Des 8: 3741-3753 2012.
23. Lindemann K, Christensen RD and Vergote I: First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC) - a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 23: 2613-2619, 2012.
24. MacFarlane M, Merrison W, Bratton SB and Cohen GM: Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 277: 36611-36616, 2002.
25. Ma L, Huang Y, Song Z, et al: Livin promotes Smac/DIABLO degradation by ubiquitin-proteasome pathway. Cell Death Differ 13: 2079-2088, 2006. (Pubitemid 44742691)
26. Fulda S, Wick W, Weller M and Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 8: 808-815, 2002.
27. Emeagi PU, Van Lint S, Goyvaerts C, et al: Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. Cancer Res 72: 1342-1352, 2012.
28. Jiang G, Zhao J, Xiao X, et al: An N-terminal Smac peptide sensitizes human prostate carcinoma cells to methyl jasmonate-induced apoptosis. Cancer Lett 302: 37-46, 2011.
29. Xiao XY, Jiang GS, Wang L, Lv L and Zeng FQ: Predominant enhancement of apoptosis induced by methyl jasmonate in bladder cancer cells: therapeutic effect of the Antp-conjugated Smac peptide. Anticancer Drugs 22: 853-863, 2011.